Zijtregtop Eline A M, Zeal Jamie, Metzger Monika L, Kelly Kara M, Mauz-Koerholz Christine, Voss Stephan D, McCarten Kathleen, Flerlage Jamie E, Beishuizen Auke
Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands.
Department of Pediatrics, University of Tennessee Health Sciences Center, Memphis, TN.
Blood Adv. 2023 Oct 24;7(20):6303-6319. doi: 10.1182/bloodadvances.2023010024.
The International Staging Evaluation and Response Criteria Harmonization for Childhood, Adolescent, and Young Adult Hodgkin Lymphoma (SEARCH for CAYAHL) seeks to provide an appropriate, universal differentiation between E-lesions and stage IV extranodal disease in Hodgkin lymphoma (HL). A literature search was performed through the PubMed and Google Scholar databases using the terms "Hodgkin disease," and "extranodal," "extralymphatic," "E lesions," "E stage," or "E disease." Publications were reviewed for the number of participants; median age and age range; diagnostic modalities used for staging; and the definition, incidence, and prognostic significance of E-lesions. Thirty-six articles describing 12 640 patients met the inclusion criteria. Most articles reported staging per the Ann Arbor (72%, 26/36) or Cotswolds modification of the Ann Arbor staging criteria (25%, 9/36), and articles rarely defined E-lesions or disambiguated "extranodal disease." The overall incidence of E-lesions for patients with stage I-III HL was 11.5% (1330/11 602 unique patients). Available stage-specific incidence analysis of 3888 patients showed a similar incidence of E-lesions in stage II (21.2%) and stage III (21.9%), with E-lesions rarely seen with stage I disease (1.1%). E-lesions likely remain predictive, but we cannot unequivocally conclude that identifying E-lesions in HL imparts prognostic value in the modern era of the more selective use of targeted radiation therapy. A harmonized E-lesion definition was reached based on the available evidence and the consensus of the SEARCH working group. We recommend that this definition of E-lesion be applied in future clinical trials with explicit reporting to confirm the prognostic value of E-lesions.
儿童、青少年和青年霍奇金淋巴瘤国际分期评估与反应标准协调项目(SEARCH for CAYAHL)旨在对霍奇金淋巴瘤(HL)中的E病变和IV期结外疾病进行恰当、统一的区分。通过PubMed和谷歌学术数据库进行文献检索,检索词为“霍奇金病”以及“结外”“淋巴外”“E病变”“E期”或“E疾病”。对纳入文献的参与者数量、中位年龄和年龄范围、用于分期的诊断方法,以及E病变的定义、发生率和预后意义进行了综述。36篇描述12640例患者的文章符合纳入标准。大多数文章报告的分期依据是Ann Arbor分期标准(72%,26/36)或Ann Arbor分期标准的Cotswolds修订版(25%,9/36),且文章很少对E病变进行定义或明确区分“结外疾病”。I - III期HL患者中E病变的总体发生率为11.5%(1330/1160故患者)。对3888例患者进行的特定分期发生率分析显示,II期(21.2%)和III期(21.9%)E病变的发生率相似,I期疾病中很少见E病变(1.1%)。E病变可能仍具有预测性,但在更有选择性地使用靶向放射治疗的现代时代,我们不能明确得出在HL中识别E病变具有预后价值的结论。基于现有证据和SEARCH工作组的共识,达成了统一的E病变定义。我们建议在未来的临床试验中应用这一E病变定义,并进行明确报告,以确认E病变的预后价值。